Ketamine (KET) Rapid Test

Ketamine testing is the process of screening a biological specimen, commonly urine, for ketamine or related metabolites. A Ketamine urine test is often used when recent exposure needs to be assessed in a fast and practical way. Urine is widely used in drug abuse testing because it is non-invasive, easy to collect, and suitable for routine screening programs.

• The Ketamine (KET) Rapid Test works as an immunoassay-based rapid test. In simple terms, the urine specimen reacts with test reagents inside the device.
• If ketamine concentration is at or above the specified cut-off, the test may show a presumptive positive result.
• This test is designed as a qualitative preliminary screening test and should be confirmed by laboratory testing where required.

• Ketamine may not always be included in basic drug screening panels. In many testing programs, ketamine must be added as a specific drug panel or tested through an expanded screening format.
• This makes a dedicated Ketamine KET Rapid Test useful for organizations that require targeted drug abuse monitoring.
• For professional environments, the KET urine test offers a fast first-level screening option before confirmatory laboratory testing.

The Ketamine (KET) Rapid Test by LARKSOIS Pharma can be used across multiple professional settings where preliminary ketamine screening support is required.

Applications

• Workplace drug testing programs
• Rehabilitation and recovery monitoring
• Clinical toxicology screening
• Forensic and institutional testing
• School, college, or sports-related screening where legally permitted
• Public safety and compliance programs
• International diagnostic distribution requirements
• Laboratory and hospital screening workflows

The 1000ng/ml cut-off means the Ketamine (KET) Rapid Test is designed to detect ketamine at or above this screening threshold. If the concentration in urine is below the cut-off, the result may appear negative. If the concentration is equal to or above the cut-off, the result may appear presumptive positive. Cut-off values help standardize screening interpretation, but sample quality, timing of specimen collection, metabolism, hydration level, storage conditions, cross-reactivity, improper handling, or reading time can influence outcomes.

Instructions

• Rapid urine-based drug abuse screening
• Designed for ketamine detection
• 1000ng/ml cut-off level
• Simple and practical test format
• Suitable for professional screening programs
• Useful for clinical, workplace, forensic, and rehabilitation settings
• Supports international drug testing requirements
• No complex instrument required for preliminary screening
• Manufactured under quality-focused production standards
• Supplied by LARKSOIS Pharma for global markets

The Ketamine (KET) Rapid Test uses an immunoassay-based rapid urine screening method for qualitative detection of ketamine exposure. It is designed to provide a preliminary screening result at the stated 1000ng/ml cut-off.

Benefits

• Urine-based rapid screening format
• 1000ng/ml ketamine cut-off
• Designed for KET drug screening
• Suitable for professional diagnostic use
• Supports fast preliminary results
• Useful for clinical, workplace, rehabilitation, forensic, and institutional workflows
• Applicable for laboratories, hospitals, diagnostic centers, and distributors
• Supports international drug screening requirements

Urine is one of the most widely used specimens for drug abuse screening because it is non-invasive, easy to collect, and practical for routine testing programs. LARKSOIS Pharma’s Ketamine (KET) Rapid Test is developed for urine specimen testing and should be used according to the product insert, sample handling instructions, and applicable testing regulations.

Guidance

• Use urine specimens only
• Use clean sample collection procedures
• Follow the product insert carefully
• Treat all urine samples as potentially biohazardous
• Interpret results within the stated reading window
• Use confirmatory testing where required by clinical, legal, workplace, forensic, or institutional policy

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

• The KET rapid urine test plays an important role in drug-of-abuse screening because ketamine misuse can create health, safety, workplace, and legal concerns.
• In professional testing programs, rapid screening helps identify samples that may require further laboratory evaluation.
• For global buyers, the Ketamine KET Rapid Test 1000ng/ml is an important product for diagnostic portfolios, drug testing panels, rehabilitation support, workplace safety programs, and forensic screening applications.

Steps

• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Ketamine (KET) Rapid Test.

Positive

A positive or non-negative result suggests that ketamine may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary and should be confirmed using a recognized laboratory method.

Negative

A negative result suggests that ketamine was not detected or was below the cut-off at the time of testing. A negative result does not always rule out exposure if testing is done outside the detection period or if the concentration is below the cut-off.

Invalid

If the valid control indicator does not appear, the test is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store in a cool and dry place
• Keep away from direct sunlight
• Do not freeze the test device
• Keep the pouch sealed until use
• Do not use after the expiry date
• Avoid using damaged or opened packaging
• Follow the temperature range mentioned on the product label

Instructions

• For professional in-vitro screening use only
• Use only urine specimens as directed
• Do not reuse the test device
• Read results only within the recommended time window
• Handle urine specimens as potentially infectious material
• Wear gloves and follow standard hygiene practices
• Do not use expired or damaged test kits
• Confirm presumptive positive results using laboratory testing
• Follow local regulations for drug testing and reporting

LARKSOIS Pharma provides international-quality pharmaceutical and diagnostic solutions for global healthcare and screening markets. The Ketamine (KET) Rapid Test is developed for professional users who require practical, dependable, and easy-to-use drug abuse testing products.

Advantages

• Global product quality approach
• Reliable drug of abuse rapid test portfolio
• Professional screening solutions
• Suitable for bulk and institutional supply
• Distributor-friendly product support
• Focus on compliance, consistency, and usability
• Practical solution for targeted ketamine urine screening